Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Lawrence A. Gervasi

Urology
SouthWest Urology - Middleburg Heights
Southwest Urology, LLC
6900 Pearl Rd, Suite 200, 
Middleburg Heights, OH 
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
SouthWest Urology - Middleburg Heights
Southwest Urology, LLC
6900 Pearl Rd, Suite 200, 
Middleburg Heights, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lawrence Gervasi is an Urologist in Middleburg Heights, Ohio. Dr. Gervasi is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Non-Muscle Invasive Bladder Cancer, UPJ Obstruction, Muscle Invasive Bladder Cancer, Prostate Cancer, and Ureteroscopy. Dr. Gervasi is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in OH
Hospital Affiliations
Parma Community General Hospital
Southwest General Health Center
Languages Spoken
English
Filipino
German
Greek
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 23 Less Insurance Carriers -

Locations

SOUTHWEST UROLOGY, LLC
6900 Pearl Rd, Suite 200, Middleburg Heights, OH 44130
Call: 440-845-0900

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


9 Clinical Trials

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC
Enrollment Status: Active_not_recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug
Study Drug: UGN-102
Study Phase: Phase 3
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Enrollment Status: Terminated
Publish Date: June 06, 2024
Intervention Type: Drug, Procedure
Study Drug: Mitomycin C
Study Phase: Phase 3
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: VERU-100
Study Phase: Phase 1/Phase 2
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Enrollment Status: Terminated
Publish Date: May 17, 2023
Intervention Type: Drug, Biological, Combination product
Study Phase: Phase 1/Phase 2
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Enrollment Status: Terminated
Publish Date: June 23, 2022
Intervention Type: Diagnostic test
PURSUIT: Prospective US Radiofrequency SUI Trial
PURSUIT: Prospective US Radiofrequency SUI Trial
Enrollment Status: Unknown
Publish Date: July 26, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Enrollment Status: Completed
Publish Date: February 05, 2019
Intervention Type: Drug
Study Phase: Not Applicable
View 8 Less Clinical Trials

3 Total Publications

Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial.
Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial.
Journal: Targeted oncology
Published: March 17, 2025
View All 3 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Steven Campbell
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Steven Campbell
Urology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (12.2 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steven Campbell is an Urologist in Cleveland, Ohio. Dr. Campbell is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Cystectomy.

Jihad Kaouk
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jihad Kaouk
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jihad Kaouk
Urology

Cleveland Clinic Main Campus

2050 East 96th Street, 
Cleveland, OH 
 (13.0 miles away)
216-444-5600
Experience:
36+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jihad Kaouk is an Urologist in Cleveland, Ohio. Dr. Kaouk has been practicing medicine for over 36 years and is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Horseshoe Kidney, Nephrectomy, and Prostatectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert Stein
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert Stein
Urology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (12.2 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Stein is an Urologist in Cleveland, Ohio. Dr. Stein is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), UPJ Obstruction, Upper Tract Urothelial Carcinoma (UTUC), Nephrectomy, and Ureteral Reconstruction.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gervasi's expertise for a condition
ConditionClose
    • Distinguished
    • Bladder Cancer
      Dr. Gervasi is
      Distinguished
      . Learn about Bladder Cancer.
      See more Bladder Cancer experts
    • Enlarged Prostate (BPH)
      Dr. Gervasi is
      Distinguished
      . Learn about Enlarged Prostate (BPH).
      See more Enlarged Prostate (BPH) experts
    • Familial Prostate Cancer
      Dr. Gervasi is
      Distinguished
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Hydronephrosis
      Dr. Gervasi is
      Distinguished
      . Learn about Hydronephrosis.
      See more Hydronephrosis experts
    • Kidney Stones
      Dr. Gervasi is
      Distinguished
      . Learn about Kidney Stones.
      See more Kidney Stones experts
    • Muscle Invasive Bladder Cancer
      Dr. Gervasi is
      Distinguished
      . Learn about Muscle Invasive Bladder Cancer.
      See more Muscle Invasive Bladder Cancer experts
    View All 13 Distinguished Conditions
    • Advanced
    • Acute Cystitis
      Dr. Gervasi is
      Advanced
      . Learn about Acute Cystitis.
      See more Acute Cystitis experts
    • Bilateral Hydronephrosis
      Dr. Gervasi is
      Advanced
      . Learn about Bilateral Hydronephrosis.
      See more Bilateral Hydronephrosis experts
    • Bladder Stones
      Dr. Gervasi is
      Advanced
      . Learn about Bladder Stones.
      See more Bladder Stones experts
    • Boils
      Dr. Gervasi is
      Advanced
      . Learn about Boils.
      See more Boils experts
    • Carbuncle
      Dr. Gervasi is
      Advanced
      . Learn about Carbuncle.
      See more Carbuncle experts
    • Empyema
      Dr. Gervasi is
      Advanced
      . Learn about Empyema.
      See more Empyema experts
    View All 11 Advanced Conditions
    • Experienced
    • Asymptomatic Bacteriuria
      Dr. Gervasi is
      Experienced
      . Learn about Asymptomatic Bacteriuria.
      See more Asymptomatic Bacteriuria experts
    • Balanitis
      Dr. Gervasi is
      Experienced
      . Learn about Balanitis.
      See more Balanitis experts
    • Bladder Outlet Obstruction
      Dr. Gervasi is
      Experienced
      . Learn about Bladder Outlet Obstruction.
      See more Bladder Outlet Obstruction experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Gervasi is
      Experienced
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Clear Cell Sarcoma
      Dr. Gervasi is
      Experienced
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    • Congenital Mesoblastic Nephroma
      Dr. Gervasi is
      Experienced
      . Learn about Congenital Mesoblastic Nephroma.
      See more Congenital Mesoblastic Nephroma experts
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved